John Maraganore is a co-founder and Executive Chair of City Therapeutics. Dr. Maraganore was the founding CEO and a director of Alnylam Pharmaceuticals from 2002-2021, where he built and led the company from early platform research on RNAi through global approval and commercialization of the first five RNAi medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, LEQVIO®, and AMVUTTRA®. Prior to Alnylam, he held senior leadership roles at Millennium Pharmaceuticals (subsequently acquired by Takeda Pharmaceutical Company) and at Biogen, and was a scientist at ZymoGenetics and the Upjohn Company earlier in his career.

Dr. Maraganore is currently Principal of JMM Innovations, a strategic consulting firm, co-Chief Executive Officer of Corsera Health, a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments. Dr. Maraganore serves on the boards of Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics, Hemab Therapeutics, and Takeda Pharmaceutical Company. He is a member of the Biotechnology Innovation Organization board, where he was chair from 2017-2019.

Dr. Maraganore received a M.S. and Ph.D. in Biochemistry and Molecular Biology and a B.A. in Biological Sciences at the University of Chicago.